Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $37.83 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Karyopharm Therapeutics Trading Up 14.8 %
Shares of NASDAQ:KPTI opened at $9.83 on Thursday. Karyopharm Therapeutics has a 1 year low of $7.61 and a 1 year high of $25.50. The firm has a fifty day moving average price of $0.84 and a 200 day moving average price of $0.82. The stock has a market capitalization of $1.24 billion, a PE ratio of -9.64 and a beta of 0.06.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Karyopharm Therapeutics
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Featured Articles
- Five stocks we like better than Karyopharm Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- Buffett’s on the Sidelines – Should You Follow?
- Investing in Construction Stocks
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.